ReportGem ReportGem

U.S. COMPANY FILING

ELI LILLY & Co — Form 10-Q filed 2026-08-05

Filed: 2026-08-05Company: ELI LILLY & CoTicker: LLYExchange: NYSEForm: 10-QReport period: 2026-06-30SEC accession: 0000059478-26-000081Event: earningsMateriality: 90

Filing text preview

Eli Lilly reported Q2 2026 revenue of $22.97B, up 47.7% YoY, and net income of $7.10B, up 25.3%. H1 revenue reached $42.77B, up 51.2%. Mounjaro and Zepbound sales surged. The company completed acquisitions of Kelonia, Centessa, and Ventyx, and issued $9B in debt. R&D and acquisition-related costs increased, and the effective tax rate rose.

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2026-08-05Fed Rate Hike Expectations Cool, Weighing on Dollar; GBP/USD Continues to Rise2026-08-21US Inflation Cooling Lowers Rate Hike Expectations, Dollar Index Continues to Weaken2026-08-21ByteTree: US Covert QE Opens, Gold Bull Market Room Fully Unlocked2026-08-21Mogul predicts gold price could surge 10-fold to $30k-50k, warns of mine expropriation risk2026-08-21US Treasury's expanded long-term bond buyback expectations boost gold; gold may continue to strengthen2026-08-21How Long Can Iran's Oil Exports Survive $170M Daily Loss and UAE Supply Cut?2026-08-218-K2026-08-05 · 8-K